BEAMBeam Therapeutics Inc.
$27.04+8.1% 1Y
$27.04
$20.6052 weeks$37.96
The business
How BEAM's business earns
Beam Therapeutics Inc. spent more than it took in: an operating loss of $393M on $147M of revenue, 12 months to Sep 30, 2026.
$393M
Operating loss · on $147M of revenue · 12 months to Sep 30, 2026
- Share count, year on year
- +2.1%
Share count, year on year · more shares than a year ago
Operating margin by fiscal year
| Year | Operating margin |
|---|---|
| FY2020 | −553167% |
| FY2021 | −757% |
| FY2022 | −556% |
| FY2023 | −47% |
| FY2024 | −654% |
| FY2025 | −275% |
Details›
- Operating margin12 months to Sep 30, 2026
- −268%
- Net margin12 months to Sep 30, 2026
- −74%
- Free cash flow margin
- −272%
- R&D as % of revenue
- 279%
- Revenue, trailing twelve months
- $147M
- Free cash flow, trailing twelve months
- −$398M
- Net income, trailing twelve months
- −$108M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Biotechnology
The closest names by size in the same industry